BioScrip® is a leading provider in comprehensive, cost-effective pharmaceutical and home care solutions. Our goal is to partner with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers to provide access to infusible medications and management solutions that optimize outcomes for chronic and other complex healthcare conditions. At BioScrip, our patients receive personalized, safe, effective and convenient infusion therapies to help improve quality of life. Our team of professionals assist each patient in every step of their office or home infusion experience.
Type
Public
HQ
Denver, US
Size (employees)
2,039 (est)
BioScrip is headquartered in Denver, US
Report incorrect company information

Key People/Management at BioScrip

Richard M. Smith

Richard M. Smith

President & CEO

BioScrip Office Locations

BioScrip has offices in Eden Prairie, Elmsford and Denver
Denver, US (HQ)
950 1600 Broadway
Eden Prairie, US
10050 Crosstown Circle
Elmsford, US
100 Clearbrook Road
Show all (3)
Report incorrect company information

BioScrip Financials and Metrics

BioScrip Financials

BioScrip's revenue was reported to be $817.19 m in FY, 2017
USD

Revenue (Q1, 2018)

168.6 m

Gross profit (Q1, 2018)

55 m

Gross profit margin (Q1, 2018), %

32.7%

Net income (Q1, 2018)

(13 m)

Market capitalization (23-May-2018)

321.2 m

Closing share price (23-May-2018)

2.5

Cash (31-Mar-2018)

30.4 m

EV

772.2 m
BioScrip's current market capitalization is $321.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

842.2 m984.1 m982.2 m935.6 m817.2 m

Revenue growth, %

17%0%(5%)

Cost of goods sold

721.3 m670 m547.9 m

Gross profit

260.9 m265.6 m269.2 m
Quarterly
USDQ1, 2018

Revenue

168.6 m

Cost of goods sold

113.5 m

Gross profit

55 m

Gross profit Margin, %

33%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

15.6 m9.6 m39.5 m

Accounts Receivable

Inventories

20 m36.2 m38 m

Current Assets

187 m176.1 m187.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

9.3 m1.5 m23.2 m1.2 m29.4 m8.1 m51.4 m2.8 m16 m40.5 m33 m30.4 m

Inventories

30.3 m34.8 m34.5 m33.8 m41.9 m42.4 m26.9 m29.1 m32.4 m33.4 m30.5 m28.8 m27.8 m41.5 m

Current Assets

222.1 m251.3 m238.8 m215.6 m212.4 m185.4 m199.4 m158.8 m199 m159.4 m176 m190.5 m170.2 m176 m

PP&E

41.1 m40 m39.9 m40 m35.9 m34.9 m34.1 m30.5 m30.8 m33.7 m30.4 m30.1 m28.7 m25 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(299.7 m)(41.5 m)(64.2 m)

Depreciation and Amortization

22.7 m21.6 m27.7 m

Inventories

(5.8 m)10 m(2.5 m)

Accounts Payable

(24.1 m)(20.5 m)689 k
Quarterly
USDQ1, 2018

Net Income

(13 m)

Depreciation and Amortization

6.5 m

Inventories

(3.5 m)

Accounts Payable

2.9 m
USDY, 2018

EV/CFO

-148.7 x

Financial Leverage

-5.9 x
Show all financial metrics
Report incorrect company information